The approval covers a generic version of Ciprodex, a prescription ear-drop suspension used to treat certain bacterial infections in children and adults. The product’s estimated US market size was $110 million for the 12 months ending June 2026.

Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (USFDA) to market its generic version of ciprofloxacin and dexamethasone otic suspension, USP, 0.3%/0.1%, adding another approved product to its portfolio in the United States.

Announced in Mumbai on 19 October 2026, the approval covers an Abbreviated New Drug Application (ANDA) for the prescription medicine. The approved product is therapeutically equivalent to Ciprodex Otic Suspension, 0.3%/0.1%, the reference listed drug identified in the company’s announcement as a product of Sandoz Inc.

The medicine is intended to treat certain bacterial ear infections in children aged six months and older, as well as adults and elderly patients, depending on the type of infection. Alembic said the US market for this formulation was estimated at $110 million for the 12 months ending June 2026, according to IQVIA data.

The approval takes Alembic’s cumulative total of USFDA ANDA approvals to 246. This includes 226 final approvals and 20 tentative approvals.

Ciprofloxacin and dexamethasone combine two medicines with different roles. Ciprofloxacin is an antibiotic that acts against susceptible bacteria. Dexamethasone is a corticosteroid that helps reduce inflammation.

The suspension is used for two types of ear infections. Acute otitis media (AOM) affects the middle ear, the space behind the eardrum. The approved use covered by this product is for children aged six months and older who have tympanostomy tubes, small tubes placed in the eardrum to help drain fluid and improve airflow.

Acute otitis externa (AOE), often called swimmer’s ear, affects the outer ear canal. It can cause pain, itching, redness and discharge. The medicine is approved for this condition in children aged six months and older, adults and elderly patients, when the infection involves susceptible bacteria.

The treatment does not cover every cause of ear pain or infection. Its use depends on the diagnosis and the bacteria involved. Patients should follow medical advice and use prescription ear drops according to the approved instructions.

An ANDA is the regulatory route used by drug companies seeking approval to sell generic versions of medicines already approved in the United States. The process allows a company to rely on the USFDA’s earlier findings on the original medicine, provided it meets the requirements for a generic product.

The applicant must show that its medicine has the required active ingredients, strength, dosage form and route of use. It must also provide evidence of bioequivalence, which means the generic medicine performs in the required way compared with the reference product. Manufacturing quality and product stability are also assessed.

For Alembic, final approval means the application has cleared the US regulator’s review. It does not, by itself, establish the launch date, the price at which the medicine will be sold or the share of the market the company may gain.

The distinction between final and tentative approval matters. A tentative approval indicates that a generic application has met the required scientific and regulatory standards but cannot yet receive final approval because of certain legal or regulatory barriers, such as remaining patent or exclusivity protections.

Alembic’s reported total of 246 approvals therefore includes two different categories: 226 final approvals and 20 tentative approvals.

The estimated US market value of $110 million for the 12 months ending June 2026 gives an indication of the commercial opportunity associated with the ear-drop formulation. The figure comes from IQVIA, a company that provides data and analysis on medicines and healthcare markets.

However, the estimate represents the market for the specified product, not Alembic’s expected revenue. Actual sales will depend on factors such as competition, pricing, supply and the company’s ability to secure orders from distributors and customers.

Generic medicines generally face price competition because several manufacturers may seek to sell products containing the same active ingredients. FDA approval can allow an eligible manufacturer to enter a market, although approval alone does not guarantee strong sales.

For healthcare providers and patients, the arrival of another approved generic option may widen the choice of suppliers. Whether it leads to lower prices or better availability will depend on market conditions after the product enters commercial sale.

The new approval adds to Alembic Pharmaceuticals’ existing record of regulatory clearances in the American market. The company’s cumulative tally of 246 ANDA approvals reflects its continuing work on generic medicines for the United States.

The latest clearance concerns a specialised liquid medicine for use in the ear. Such products require the correct formulation, strength and quality, alongside compliance with the regulator’s requirements for their intended use.

The approval announced on 19 October 2026 permits Alembic to market the specified generic product, subject to applicable regulatory requirements. The company has not provided a launch date or a forecast of sales in the announcement.

For the pharmaceutical industry, the next measure of the approval’s commercial value will be how the product performs after entering the market. For patients, the practical outcome will depend on whether the medicine becomes available through healthcare providers and pharmacies at a suitable price.

Must Read: